Human Longevity announced that its board has appointed David Karow interim CEO. Karow previously served as HLI's chief of radiogenomics. Prior to HLI, Karow spent twenty years in research, clinical practice, and training at the University of California, San Diego, the University of California, Los Angeles, and the University of Michigan.
George Golumbeski, Onaiza Cadoret-Manier, Fred Kohler, Angela Lai
Grail has added to its executive team, hiring George Golumbeski as president, Onaiza Cadoret-Manier as chief commercial officer, and Fred Kohler as vice president of people. The firm has also promoted Angela Lai to chief technology officer.
Golumbeski most recently served as executive vice president of business development for Celgene, and currently serves on the boards of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. He will replace Ken Drazan as president, who has stepped down to work on helping early-stage start-up firms secure funding. Drazan will continue to serve as an advisor to Grail. Golumbeski will also join Grail's board of directors.
Cadoret-Manier joins Grail from Genentech where she was vice president of the respiratory franchise. Previously, she held various senior management positions overseeing sales and marketing for several products at Genentech, Pfizer, Amylin Pharmaceuticals, and Quest Diagnostics.
Kohler has joined Grail from Roche, where he most recently led transformation work. Kohler previously worked at Autodesk and Juniper Networks, where he held a variety of human resources roles.
Lai has served as vice president of clinical technology at Grail since July 2016. She was responsible for building Grail's software systems team and supporting the company's clinical studies.
Violaine Mélen and Stéphane Cruveiller
PathoQuest has appointed Violaine Mélen as its head of quality assurance and regulatory affairs. In the new position, Mélen will oversee the maintenance of product quality and compliance in line with the firm's quality management system, while also leading the firm's regulatory strategies. She has more than 12 years of experience in regulatory affairs, quality assurance, and clinical affairs within the biotech and pharmaceutical industries. Mélen previously worked at Bio-Rad Laboratories where she was responsible for implementing risk management procedures with a specific focus on infectious disease.
In addition, PathoQuest has appointed Stéphane Cruveiller as its chief technology information officer. As CTIO, Cruveiller will be responsible for the technical aspects of the firm's bioinformatics pipeline and alignment information technology-related development initiatives with its business goals. Cruveiller previously served as team leader at the François Jacob Institute of Biology - Genoscope of the French Alternative Energies and Atomic Energy Commission at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.